TVRD Tvardi Therapeutics Inc.

Price (delayed)

$3.06

Market cap

$28.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.65

Enterprise value

$9.03M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in ...

Highlights
TVRD's debt has dropped by 100% year-on-year and by 13% since the previous quarter
Tvardi Therapeutics's EPS has soared by 88% YoY and by 33% from the previous quarter
The quick ratio has dropped by 93% year-on-year and by 20% since the previous quarter
Tvardi Therapeutics's equity has decreased by 31% from the previous quarter

Key stats

What are the main financial stats of TVRD

TVRD stock price

How has the Tvardi Therapeutics stock price performed over time
Intraday
3.73%
1 week
-12.32%
1 month
-13.56%
1 year
-87.43%
YTD
-28.84%
QTD
-3.77%

Financial performance

How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.45M
Net income
-$15.44M
Gross margin
N/A
Net margin
N/A
TVRD's net income has soared by 56% YoY and by 15% QoQ
Tvardi Therapeutics's operating income has increased by 12% YoY but it has decreased by 10% from the previous quarter

Price vs fundamentals

How does TVRD's price correlate with its fundamentals

Growth

What is Tvardi Therapeutics's growth rate over time

Valuation

What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
1.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Tvardi Therapeutics's EPS has soared by 88% YoY and by 33% from the previous quarter
The P/B is 68% lower than the last 4 quarters average of 5.9 and 56% lower than the 5-year quarterly average of 4.3
Tvardi Therapeutics's equity has decreased by 31% from the previous quarter

Efficiency

How efficient is Tvardi Therapeutics business performance
TVRD's ROA is up by 38% YoY and by 7% QoQ
Tvardi Therapeutics's return on equity has increased by 35% QoQ

Dividends

What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TVRD.

Financial health

How did Tvardi Therapeutics financials performed over time
The total assets is 128% more than the total liabilities
The quick ratio has dropped by 93% year-on-year and by 20% since the previous quarter
Tvardi Therapeutics's current ratio has plunged by 93% YoY and by 21% from the previous quarter
TVRD's debt is 99% smaller than its equity
The company's debt to equity has surged by 100% YoY
TVRD's debt has dropped by 100% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.